A Rollercoaster Plunge into 2022

At the same time last year we were very much hoping that the extraordinary research and clinical efforts deployed in response to the pandemic outbreak would mean that we would have stepped out of the rollercoaster wagon this year.[1] But here we are in early 2022: the roller coaster elevating again ready for the next vertical plunge. On this ride, however, we came over unprecedented challenges and worldwide scientific collaboration towards vaccine development was accomplished at a speed and efficiency never imaginable so far. As it became evident thrombosis is playing an intrinsic part of COVID-19, our scientific community naturally fully engaged in this race against the disease. In this New Year Editorial, we reflect back on this rollercoaster year, which 2021 has presented to us all, and project ourselves into the New Year 2022.

As in 2020,[2] we have continued to receive a high proportion of COVID-19-related submissions in 2021, which translated in many COVID-19 publications as reflected in the Editor's Choice published in this issue.[3] As always, we are indebted to our production team as well as our highly reactive reviewers and Editors who have responded to the urgent characteristic of the data and ensured fast track publications without neglecting less urgent but nonetheless fundamental findings.

We are pleased that our impact factor has risen to 5.723 for 2020, meaning Thrombosis and Haemostasis (T&H) now ranks 10th out of 65 in the peripheral vascular disease category. Our percentile index in the hematology and peripheral vascular disease category which reflects the impact of T&H in comparison to others in the field has also risen to 85%. We continue to serve as a link journal for the European Society of Cardiology Working Groups on Thrombosis and on Atherosclerosis and Vascular Biology, as well as being the official journal of the Society of Thrombosis and Haemostasis Research (GTH), the Spanish (SETH) Society on Thrombosis and Haemostasis, and the Australian Vascular Biology Society (AVBS).

Publication History

Received: 07 December 2021

Accepted: 07 December 2021

Article published online:
17 January 2022

• References

• 1 Lip GYH, Rigby A, Weber C. Looking Back on 2020, Looking Forward to 2021. Thromb Haemost 2021; 121 (01) 1-3
• 2 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2020 Editors' Choice Papers. Thromb Haemost 2021; 121 (01) 109-114
• 3 Weber CRA, Lip GYH. Thrombosis and Haemostasis 2021 Editors' Choice Papers. Thromb Haemost 2022; 123 (01) 163-170
• 4 Henning C, Branopolski A, Follert P. et al. Endothelial β1 integrin-mediated adaptation to myocardial ischemia. Thromb Haemost 2021; 121 (06) 741-754
• 5 Tian J, Adams MJ, Tay JWT. et al. Estradiol-responsive miR-365a-3p interacts with tissue factor 3'UTR to modulate tissue factor-initiated thrombin generation. Thromb Haemost 2021; 121 (11) 1483-1496
• 6 Vilar R, Lukowski SW, Garieri M, Di Sanza C, Neerman-Arbez M, Fish RJ. Chemical modulators of fibrinogen production and their impact on venous thrombosis. Thromb Haemost 2021; 121 (04) 433-448
• 7 Aliotta A, Bertaggia Calderara D, Zermatten MG, Alberio L. Sodium-calcium exchanger reverse mode sustains dichotomous ion fluxes required for procoagulant COAT platelet formation. Thromb Haemost 2021; 121 (03) 309-321
• 8 Yamashita A, Nishihira K, Gi T. et al. Pathological features of ruptured coronary plaque and thrombus interfaces: fibrin and von Willebrand factor as platelet scaffolds on rupture sites. Thromb Haemost 2021; 121 (02) 234-241
• 9 Billett HH, Reyes-Gil M, Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 2020; 120 (12) 1691-1699
• 10 de Jong A, Dirven RJ, Boender J. et al. Ex vivo improvement of a von Willebrand disease type 2A phenotype using an allele-specific small-interfering RNA. Thromb Haemost 2020; 120 (11) 1569-1579
• 11 Hsu L-W, Chen P-W, Chang W-T, Lee WH, Liu PY. The role of ROCK in platelet-monocyte collaborative induction of thromboinflammation during acute coronary syndrome. Thromb Haemost 2020; 120 (10) 1417-1431
• 12 Fanikos J, Murwin D, Gruenenfelder F. et al. Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program. Thromb Haemost 2020; 120 (01) 27-35
• 13 Akhmedov A, Montecucco F, Costantino S. et al. Cardiomyocyte-specific JunD overexpression increases infarct size following ischemia/reperfusion cardiac injury by downregulating Sirt3. Thromb Haemost 2020; 120 (01) 168-180
• 14 Paterson GG, Young JM, Willson JA. et al. Hypoxia modulates platelet purinergic signalling pathways. Thromb Haemost 2020; 120 (02) 253-261
• 15 Izquierdo I, Barrachina MN, Hermida-Nogueira L. et al. A comprehensive tyrosine phosphoproteomic analysis reveals novel components of the platelet CLEC-2 signaling cascade. Thromb Haemost 2020; 120 (02) 262-276
• 16 Chueh T-H, Cheng Y-H, Chen K-H, Chien CT. Thromboxane A2 synthase and thromboxane receptor deletion reduces ischaemia/reperfusion-evoked inflammation, apoptosis, autophagy and pyroptosis. Thromb Haemost 2020; 120 (02) 329-343
• 17 Tahir S, Wagner AH, Dietzel S. et al. Endothelial CD40 mediates microvascular von Willebrand factor-dependent platelet adhesion inducing inflammatory venothrombosis in ADAMTS13 knockout mice. Thromb Haemost 2020; 120 (03) 466-476
• 18 Wan LM, Zhang SK, Li SB. et al. Heparanase facilitates PMA-induced megakaryocytic differentiation in K562 cells via interleukin 6/STAT3 pathway. Thromb Haemost 2020; 120 (04) 647-657
• 19 Hearn JI, Green TN, Chopra M. et al. N-methyl-D-aspartate receptor hypofunction in Meg-01 cells reveals a role for intracellular calcium homeostasis in balancing megakaryocytic-erythroid differentiation. Thromb Haemost 2020; 120 (04) 671-686
• 20 Smadja DM, Chocron R, Rossi E. et al. Autoregulation of pulsatile bioprosthetic total artificial heart is involved in endothelial homeostasis preservation. Thromb Haemost 2020; 120 (09) 1313-1322
• 21 Gencer S, Lacy M, Atzler D, van der Vorst EPC, Döring Y, Weber C. Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. Thromb Haemost 2020; 120 (12) 1629-1641
• 22 Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. Thromb Haemost 2020; 120 (12) 1642-1653
• 23 Waite AAC, Hamilton DO, Pizzi R, Ageno W, Welters ID. Hypercoagulopathy in severe COVID-19: implications for acute care. Thromb Haemost 2020; 120 (12) 1654-1667
• 24 Polzin A, Dannenberg L, Thienel M. et al. Noncanonical effects of oral thrombin and factor Xa inhibitors in platelet activation and arterial thrombosis. Thromb Haemost 2021; 121 (02) 122-130
• 25 Huang J, Huang S, Ma Z. et al. Ibrutinib suppresses early megakaryopoiesis but enhances proplatelet formation. Thromb Haemost 2021; 121 (02) 192-205
• 26 Potpara TS, Lip GYH, Blomstrom-Lundqvist C. et al. The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation. Thromb Haemost 2021; 121 (03) 270-278
• 27 Vayne C, Nguyen T-H, Rollin J. et al. Characterization of new monoclonal PF4-specific antibodies as useful tools for studies on typical and autoimmune heparin-induced thrombocytopenia. Thromb Haemost 2021; 121 (03) 322-331
• 28 Garcia A, Dunoyer-Geindre S, Fish RJ, Neerman-Arbez M, Reny JL, Fontana P. Methods to investigate miRNA function: focus on platelet reactivity. Thromb Haemost 2021; 121 (04) 409-421
• 29 Locke M, Longstaff C. Extracellular histones inhibit fibrinolysis through noncovalent and covalent interactions with fibrin. Thromb Haemost 2021; 121 (04) 464-476
• 30 Basu MK, Massicano F, Yu L. et al. Exome sequencing identifies abnormalities in glycosylation and ANKRD36C in patients with immune-mediated thrombotic thrombocytopenic purpura. Thromb Haemost 2021; 121 (04) 506-517
• 31 Atiq F, van de Wouw J, Sorop O. et al. Endothelial dysfunction, atherosclerosis, and increase of von Willebrand factor and factor VIII: a randomized controlled trial in swine. Thromb Haemost 2021; 121 (05) 676-686
• 32 Schilling U, Dingemanse J, Dobrow M. et al. Insights from in vitro and clinical data to guide transition from the Novel P2Y12 antagonist selatogrel to clopidogrel, prasugrel, and ticagrelor. Thromb Haemost 2021; 121 (06) 755-766
• 33 Arroyo AB, Águila S, Fernández-Pérez MP. et al. miR-146a in cardiovascular diseases and sepsis: an additional burden in the inflammatory balance?. Thromb Haemost 2021; 121 (09) 1138-1150
• 34 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. Thromb Haemost 2021; 121 (11) 1395-1399
• 35 Gissler MC, Scherrer P, Anto-Michel N. et al. Deficiency of endothelial CD40 induces a stable plaque phenotype and limits inflammatory cell recruitment to atherosclerotic lesions in mice. Thromb Haemost 2021; 121 (11) 1530-1540
• 36 Fabris E, Korjian S, Coller BS. et al. Pre-hospital antiplatelet therapy for STEMI patients undergoing primary percutaneous coronary intervention: what we know and what lies ahead. Thromb Haemost 2021; 121 (12) 1562-1573
• 37 Wan J, Konings J, de Laat B, Hackeng TM, Roest M. Added value of blood cells in thrombin generation testing. Thromb Haemost 2021; 121 (12) 1574-1587
• 38 Vaughan CJ, Cronin H, Ryan PM, Caplice NM. Obesity and COVID-19: a Virchow's triad for the 21st century. Thromb Haemost 2020; 120 (11) 1590-1593